Advanced Filters
noise

heart-failure Clinical Trials

A listing of heart-failure medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 840 clinical trials
S Stephen Wright, PhD

Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction

The heart is a pump that must both fill and empty effectively to move blood; if it cannot move enough, heart failure may ensue. Approximately half of all adults living with heart failure have a form where the heart stiffens, which impairs its ability to fill. This form of heart …

40 years of age All Phase N/A
H Haiyan Wang, MD

Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction

The goal of this observational study is to evaluating myocardial stiffness in patients with heart failure with preserved ejection fraction (HFpEF) by intrinsic wave velocity propagation (IVP). The main questions it aims to answer are: Whether myocardial stiffness assessed by IVP in patients with HFpEF Increased. Whether IVP is related …

18 - 80 years of age All Phase N/A
J Justin A Steggerda, M.D.

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.

18 years of age All Phase N/A
M Mark Chandy, MD PhD

iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease

The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood …

18 - 80 years of age All Phase N/A
N Nir Uriel, MD

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Heart failure is a world epidemic. LVADs are increasingly used as they have demonstrated improved survival rates compared to optimal medical management. Improving outcomes have been seen with the newer LVAD technology, the HeartMate 3 (Abbott, Chicago, IL), however, hemocompatibility related adverse events, including thrombosis and bleeding, are still a …

18 years of age All Phase 4

Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients …

18 - 80 years of age All Phase N/A
S Steen Hyldgaard, MD

Biomarkers as Predictors of Chronic Heart Failure in Patients With Type 2 Diabetes

A cohort study on patients with type 2 diabetes to investigate possible biomarkers as predictors of chronic heart failure.

50 years of age All Phase N/A
L Louis L Handoko, Dr.

Multiple-biomarker Approach for Individualized Treatment of Heart Failure with Preserved Ejection Fraction

The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with HFpEF. Moreover several secondary objectives will be investigated.

18 years of age All Phase N/A
C Chih-Cheng Wu, PhD

Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease

In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding their efficacy and safety in patients under chronic hemodialysis. As the primary target of SGLT2i …

20 years of age All Phase 4
D Diana Albers

A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

18 years of age All Phase N/A

Simplify language using AI